The CTCL-specific strategies in future therapies targeting the CD47-SIRPα axis may go in two directions: agents without an Fc fragment to engage only macrophages and therapies utilizing Fc fragments to boost ADCC and tumor killing by NK cells. Here, SIRPA is linked to neoplasm.